20:22 , Oct 24, 2017 |  BC Extra  |  Company News

Management tracks: Five Prime, CytoSen

Cancer play Five Prime Therapeutics Inc. (NASDAQ:FPRX) promoted Aron Knickerbocker to president and CEO from COO, effective Jan. 1, 2018. He succeeds Lewis Williams, who will become executive chairman. Cell therapy company CytoSen Therapeutics Inc....
22:20 , Jan 6, 2017 |  BioCentury  |  Finance

Tiers of disappointment

A bad year for biotech was closed with an even worse 4Q16 as volatility ahead of the U.S. elections and continued concerns around drug pricing held every market cap band in the red despite a...
22:01 , Dec 30, 2016 |  BC Week In Review  |  Company News

BioInvent, Pfizer deal

BioInvent and Pfizer partnered to develop antibodies against tumor-associated myeloid cells. BioInvent will receive upfront and near-term R&D payments totaling $10 million, including a $6 million equity investment in which the pharma will purchase 21.9...
01:42 , Dec 30, 2016 |  BC Week In Review  |  Clinical News

BI-505: Ph II discontinued

BioInvent discontinued an open-label, U.S. Phase II trial evaluating IV BI-505 as an add-on therapy in about 90 patients undergoing autologous stem cell transplantation (ASCT) with high-dose melphalan. The decision follows an FDA clinical hold...
00:10 , Dec 22, 2016 |  BC Extra  |  Company News

BioInvent, Pfizer in cancer antibody deal

BioInvent International AB (SSE:BINV) gained SEK0.63 (32%) to SEK2.63 after announcing a partnership with Pfizer Inc. (NYSE:PFE) to develop antibodies against tumor-associated myeloid cells. BioInvent will receive upfront and near-term R&D payments totaling $10 million,...
23:21 , Nov 10, 2016 |  BC Week In Review  |  Clinical News

BI-505: Ph II hold

BioInvent said FDA placed a clinical hold on an open-label, U.S. Phase II trial of IV BI-505 as an add-on therapy in about 90 patients undergoing autologous stem cell transplantation (ASCT) with high-dose melphalan. The...
23:50 , Nov 8, 2016 |  BC Extra  |  Clinical News

BioInvent MM candidate on clinical hold

BioInvent International AB (SSE:BINV) sagged SEK0.53 (22%) to SEK1.88 after the company said FDA placed a clinical hold on the company's Phase II study of BI-505 as an add-on therapy in patients with multiple myeloma...
07:00 , May 9, 2016 |  BC Week In Review  |  Clinical News

TB-403: Phase I/IIa started

Oncurious and BioInvent began an open-label, U.S. Phase I/IIa of IV TB-403 in >=27 patients ages 6 months to 18 years old. The dose-escalation Phase I portion will test 20-175 mg/kg TB-403. The Phase IIa...
07:00 , Apr 25, 2016 |  BC Week In Review  |  Clinical News

BI-505: Phase II started

BioInvent began an open-label, U.S. Phase II trial to evaluate IV BI-505 as an add-on therapy in about 90 patients undergoing autologous stem cell transplantation (ASCT). BioInvent International AB (SSE:BINV), Lund, Sweden   Product: BI-505...
08:00 , Feb 22, 2016 |  BioCentury  |  Finance

Reinventing BioInvent

A proposed financing by BioInvent International AB (SSE:BINV) would give the cancer antibody company new life to reach clinical proof of concept for three assets and fund preclinical immuno-oncology programs that it had been forced...